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Abstract
Background: It has become increasingly clear that β -cell failure plays a critical role in the
pathogenesis of type 2 diabetes. Free-radical mediated β -cell damage has been intensively studied
in type 1 diabetes, but not in human type 2 diabetes. Therefore, we studied the protein expression
of the DNA repair enzyme Ogg1 in pancreases from type 2 diabetics. Ogg1 was studied because it
is the major enzyme involved in repairing 7,8-dihydro-8-oxoguanosine DNA adducts, a lesion
previously observed in a rat model of type 2 diabetes. Moreover, in a gene expression screen, Ogg1
was over-expressed in islets from a human type 2 diabetic.
Methods: Immunofluorescent staining of Ogg1 was performed on pancreatic specimens from
healthy controls and patients with diabetes for 2–23 years. The intensity and islet area stained for
Ogg1 was evaluated by semi-quantitative scoring.
Results: Both the intensity and the area of islet Ogg1 staining were significantly increased in islets
from the type 2 diabetic subjects compared to the healthy controls. A correlation between
increased Ogg1 fluorescent staining intensity and duration of diabetes was also found. Most of the
staining observed was cytoplasmic, suggesting that mitochondrial Ogg1 accounts primarily for the
increased Ogg1 expression.
Conclusion: We conclude that oxidative stress related DNA damage may be a novel important
factor in the pathogenesis of human type 2 diabetes. An increase of Ogg1 in islet cell mitochondria
is consistent with a model in which hyperglycemia and consequent increased β -cell oxidative
metabolism lead to DNA damage and the induction of Ogg1 expression.
Background
It has become increasingly clear that β -cell failure plays a
critical role in the pathogenesis of type 2 diabetes (for a re-
view see [1]). Normally, increased peripheral insulin re-
sistance and consequent insulin demand are met by
increased β -cell activity and/or β -cell mass. Failure of β -
cells to meet the demand for increased insulin secretion
leads to overt diabetes [2–4]. The mechanisms behind the
Published: 25 April 2002
BMC Endocrine Disorders 2002, 2:2
Received: 17 January 2002
Accepted: 25 April 2002
This article is available from: http://www.biomedcentral.com/1472-6823/2/2
© 2002 Tyrberg et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, pro-
vided this notice is preserved along with the article's original URL.BMC Endocrine Disorders 2002, 2 http://www.biomedcentral.com/1472-6823/2/2
Page 2 of 10
(page number not for citation purposes)
β -cell failure are less well understood, but a number of fac-
tors have been implicated, including hyperlipedemia [5],
supraphysiological concentrations of circulating glucose
[6,7], formation of intra- and extra-cellular islet amyloid
deposits [8], or a combination of these factors. Amyloid
deposition has been shown to trigger β -cell apoptosis and
necrosis [9]. Lipotoxicity causes β -cell dysfunction by in-
hibiting insulin secretion [10] and by direct cytotoxicity
[11]. β -cell glucotoxicity has been described both in ro-
dents and humans leading to apoptosis, decreased cell di-
vision and effects on transcriptional factor expression
[6,7,12–16]. However, the relative contributions of these
different mechanisms to β -cell failure remains unknown.
Free radicals and DNA-damage in diabetes
Free-radicals (e.g., superoxide, hydroxyl radicals, nitric ox-
ide and peroxynitrite) have long been thought to be a key
element in the cellular dysfunction and death that are cen-
tral to the pathogenesis of many aspects of diabetes. In
type 1 diabetes, it has been shown that inflammatory cy-
tokines play a central role in the destruction of insulin
producing β -cells [17–19], resulting in the production of
oxygen-derived free radicals that induce DNA-damage
and apoptosis in both rodent and human β -cells [20–25].
In both type 1 and type 1, as well as, type 2 diabetes, the
role of free radicals in diabetic complications is well stud-
ied. The most prominent feature of diabetes, hyperglyc-
emia, is believed to augment free radical production [26],
probably due to the increased mitochondrial oxidative
metabolism that is secondary to a high intracellular glu-
cose concentration. Glucose also leads to advanced glyca-
tion end products, which initiate free radical cascades and
are toxic to cells, including β -cells [27,28].
Free radicals cause damage to cells by various mecha-
nisms, resulting in damage to proteins, lipids, and nucleic
acids, i.e., virtually all cellular structures. In particular, free
radicals may lead to nuclear and mitochondrial DNA
damage and mutations, causing diminished proliferative
capacity, premature cellular senescence, and impaired mi-
tochondrial function [29,30]. For the β -cell, one of the
most metabolically active cells in the body, mitochondrial
function is essential, and diabetes is a prominent feature
of many primary disorders of mitochondrial function
[30].
While free radicals play a central role in the pathogenesis
of many aspects of diabetes and it is known that free rad-
icals can cause DNA damage, direct evidence is sparse for
DNA damage in the pathogenesis of β -cell failure in type
2 diabetes. The exceptions are a study in which it was re-
ported that the oxygen radical derived DNA adduct 7,8-di-
hydro-8-oxoguanosine (8-OH-dG) is present in the islets
of diabetic Goto-Kakizaki rats, a model of type 2 diabetes
[31]. Also, after submission of the present study, it was re-
ported that an increased number of 8-OH-dG positive is-
let cells is observed in pancreata from human type 2
diabetic subjects. In that study, an increased number of
cells with DNA damage correlated with a decreased β -cell
mass [32].
Hypothesis
We hypothesized that oxidative DNA damage plays a role
in the β -cell dysfunction and loss that occurs in human
type 2 diabetes. To test this hypothesis, we screened the
gene expression patterns of islets from a normal control
and a type 2 diabetic subject with Affymetrix gene chip ar-
rays, with special reference to genes involved in DNA re-
pair (Tyrberg & Levine, unpublished data). One gene that
was over-expressed in islets from the type 2 diabetic sub-
ject, was the DNA glycosylase 8-OxoG DNA glycosylase
(Ogg1). This enzyme is the major repair enzyme involved
in the defense against accumulation of the 8-OH-dG ad-
ducts discussed above. In light of the previous publication
on the role of 8-OH-dG adducts in a rat model of type 2
diabetes [31], and the finding that the Ogg1 gene was
over-expressed in human type 2 diabetes, we evaluated
the expression of Ogg1 protein in pancreas specimens
from type 2 diabetic and healthy subjects, as a marker for
β -cell oxidative DNA damage in type 2 diabetes.
Methods
Tissue collection
Specimens from human pancreata were collected in La
Jolla, CA; Sofia, Bulgaria; Seoul, South Korea and São Pao-
lo, Brazil, post mortem or post surgery. Normal control
subjects were never diagnosed with any form of diabetes
while patients with type 2 diabetes had been diagnosed 2,
7, 15, 20 or 23 years before the specimens were collected.
Diagnoses were based on hospital records. The patient
with a 23 year history of diabetes also had a history of al-
coholism. None of the subjects had a history of receiving
cancer therapy, a possible confounding factor in the anal-
ysis of DNA damage. More detailed patient records are
found in Table 1.
Immunofluorescent staining and fluorescence microscopy
Sections from human pancreata were double stained for
Ogg1 and somatostatin, as a marker for the islets, with
rabbit anti-human Ogg1 (Novus Biologicals, Littleton,
CO) and goat anti-human somatostatin antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA), after antigen re-
trieval by boiling for 10 min in acidic antigen retrieval so-
lution (Biogenex, San Ramon, CA). Antibody binding was
detected with an Alexa488 donkey anti-rabbit antibody
(Molecular Probes, Eugene, OR) and an Alexa590 donkey
anti-goat antibody (Molecular Probes). All sections were
finally counter-stained with nuclear DAPI staining (Mo-
lecular Probes), and mounted with anti-fading mounting
media (DAKO fluorescent mounting media, DAKO, Glos-BMC Endocrine Disorders 2002, 2 http://www.biomedcentral.com/1472-6823/2/2
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trup, Denmark). To evaluate the specificity of the Ogg1
antibody, slides were stained with fluorescent secondary
antibody alone, which resulted in no background staining
(data not shown). Also, as a positive control, pancreas
from a mouse injected with the oxidative radical inducing
agent alloxan [33], were stained one day after the injec-
tion, with a marked increase of Ogg1 nuclear and cyto-
plasmic staining as a result (data not shown).
Tissue sections were examined in a fluorescent micro-
scope with 200–400×  magnification. The pancreatic islets
were evaluated blindly with semi-quantitative morpho-
logical scoring of fluorescent intensity: 0, no or very weak
Ogg1 staining; 1, moderate Ogg1 staining; and 2, strong
Ogg1 staining. They were also scored for Ogg1 positive is-
let area as follows: 0; no or very small area of the islet
stained for Ogg1; 25, approximately 25% of the islet area
was Ogg1 positive; 50, approximately 50%; 75, approxi-
mately 75%; and 100, approximately 100%. The total
number of islets evaluated in the five pancreata from type
2 diabetic patients were 232 (46.4± 8.5 per pancreas) and
in the seven pancreata from normal controls: 306 (43.7 ±
8.6 per pancreas). Sections were evaluated live in the flu-
orescence microscope with a combined filter for green
and red fluorescence, which means that camera exposure
time and other camera settings, did not influence the in-
tensity of the Ogg1 staining. Also, the Alexa dyes are very
stable fluorophores, even under UV light exposure, so that
fading is unlikely to be a significant issue in influencing
the results [34].
Ethics
Human tissue collection were approved by the respective
local human IRBs (UCSD, La Jolla, CA; Veterans Hospital,
La Jolla, CA; Military Medical Academy, Sofia, Bulgaria;
University Hospital of São Paolo, São Paolo, Brazil; The
Catholic University of Korea, Seoul, South Korea). No in-
formation that would identify the subjects was provided.
Statistical analysis
Data are presented as means ± SEM. The average semi-
quantitative unparametric morphological scores for each
individual was compared with Mann-Whitney's unpara-
metric test.
Results
Pancreatic paraffin sections from five type 2 diabetic sub-
jects and seven healthy controls were compared by immu-
nohistochemistry for Ogg1. Co-staining for somatostatin
as a marker of islets of Langerhans was performed (Fig. 1).
Somatostatin rather than insulin was chosen as an islet
marker because insulin expression can be significantly de-
creased in islets from patients with longstanding type 2 di-
abetes.
Two parameters were chosen to measure islet Ogg1 ex-
pression. The percentage of the islet that stained positively
for Ogg1 was used as a measure of the number of Ogg1-
expressing cells. The intensity of the Ogg1 staining was
used as a measure of the level of Ogg1 expression in posi-
tive cells. By semi-quantitative scoring, both the intensity
and the area of Ogg1 staining were significantly increased
(P < 0.05 and P < 0.02, respectively) in islets from the type
2 diabetic subjects compared to the healthy controls (Fig.
2,3,4,5). Interestingly, the Ogg1 fluorescent staining in-
tensity, but not the percent positive islet area, increases
with increasing duration of diabetes (Fig. 6). Pancreatic
exocrine tissue expressed Ogg1 at various degrees (Fig. 1),
but no correlation was found with type 2 diabetes (data
not shown).
Discussion
This study demonstrates that the enzyme Ogg1, which is
involved in the repair of oxidative DNA damage, is up-reg-
ulated in the islets of patients with type 2 diabetes. This is
consistent with the hypothesis that oxidative DNA dam-
age is an important factor in the β -cell failure that plays a
role in the pathogenesis of human type 2 diabetes.
We interpret the upregulation of Ogg1 as a response to an
increased level of 8-OH-dG DNA, the lesion that it repairs.
Increases in Ogg1 activity and expression have been found
Table 1: Clinical information on the human subjects.
Identity letter or 
diabetes duration (yr)
Age Diabetes 
treatment
Cause of death or 
*cause of extirpation
Controls:
a5 7 # N/A *Mild pancreas rejection
b 66 N/A Mesenterial thrombosis
c4 0 N / A *Cerebral infarct
d5 7 N / A *Pancreatic cystadenoma
e- N / A -
f 49 N/A Myocardial tamponade
g- N / A -
Diabetics:
2 53 SU Myocardial infarct
7 58 SU Myocardial infarct
15 72 Diet Myocardial insufficiency
20 69 Insulin / SU Myocardial insufficiency
23 57 Diet *Chronic pancreatitis
The evaluated tissues were taken adjacent to pathological area, when-
ever applicable. #Age of pancreas donor not known. SU, sulphonylu-
rea. No data could be recovered regarding subject e and g. Late onset 
type 1 diabetes were excluded based on histological absence of lym-
phocytes adjacent to islets.BMC Endocrine Disorders 2002, 2 http://www.biomedcentral.com/1472-6823/2/2
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Figure 1
Ogg1 immunofluorescent staining in human pancreata. Ogg1 staining (green) and somatostatin (red), as a marker for
islets of Langerhans, in normal human pancreata (A, C, E); and pancreata from type 2 diabetic subjects (B, D, F). Micrograph A
is representative of an islet with no or very little Ogg1 staining; B of an islet with moderate staining intensity of 25% of the area;
C, strong staining of 50% of the area; D, strong staining of 100% of the area; E, strong staining of 75% of the area; and F, strong
staining of 100% of the area. Notably, the surrounding exocrine tissue is positive for Ogg1 at varying degrees (B and D vs. the
rest). The micrographs were captured with identical camera settings. Original optical magnification 400× .BMC Endocrine Disorders 2002, 2 http://www.biomedcentral.com/1472-6823/2/2
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by a number of investigators [35–37]. Although antibod-
ies to 8-OH-dG exist [38], Ogg1 was used as a surrogate
for the amount of oxidative DNA damage. The reason for
this is that we found high levels of background staining
with the anti-8-OH-dG antibodies, which is not unusual
when using streptavidin/biotin detection systems in im-
munohistochemistry [39]. Unfortunately, secondary anti-
bodies directly linked to a fluorophore or a detection
enzyme were not sensitive enough to detect the 8-OH-dG
adduct in our hands.
The mechanism by which Ogg1 protein is increased in
type 2 diabetic islets is unknown. The promoter of the
Ogg1 gene does not have a TATA box [40], but Ogg1 is dif-
ferentially expressed in the rat CNS, and its expression is
increased after mouse forebrain ischemia-reperfusion
[35,36], suggesting that regulation occurs, either at the
transcriptional or post-transcriptional level. Unfortunate-
ly, there have been no studies of the effects of long-term
chronic increases in oxidative DNA damage on Ogg1 ex-
pression. The association between the duration of diabe-
tes and Ogg1 levels (Fig. 6) suggests that such long-term
exposure may be important for Ogg1 up-regulation.
Most of the staining observed was detected in the cyto-
plasm of the islet cells. As Ogg1 either is sublocalized into
the nucleus or the mitochondria, this indicates that
β Ogg1, the mitochondrial form of Ogg1, accounts for the
observed increase. β Ogg1 is an alternatively spliced form
of Ogg1 that contains a mitochondrial targeting signal in
the C-terminal portion of the protein [41]. Specific upreg-
ulation of mitochondrial but not nuclear Ogg1 occurs
during aging in rodents [42]. A specific increase of Ogg1
in islet cell mitochondria is consistent with the idea that
increased β -cell mitochondrial oxidative metabolism due
to hyperglycemia is a major factor behind the DNA dam-
age. In a study published after this report was submitted,
an increased number of 8-OH-dG positive islet cells in hu-
Figure 2
Islet area stained for Ogg1. Islets were semi-quantitatively scored according to Methods into five different groups depend-
ing on the percentage of the area stained positive for Ogg1. Islets from type 2 diabetic subjects (2, 7, 15, 20, 23 years of diabe-
tes duration, red) have significantly larger areas stained for Ogg1 (P < 0.05) than islets from healthy controls (a-g, green).BMC Endocrine Disorders 2002, 2 http://www.biomedcentral.com/1472-6823/2/2
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man type 2 diabetic subjects was observed [32]. The stain-
ing was found to be mainly nuclear in contrast to the
cytoplasmic Ogg1 staining found in the present report.
Unfortunately, we were unable to obtain specific staining
with antibodies to 8-OH-dG. However, the nuclear local-
ization of 8-OH-dG [32] and the increased Ogg1 reported
here are consistent with a model in which mitochondrial
Ogg1 is up-regulated but nuclear Ogg1 is not, leading to
an increase in nuclear but not mitochondrial 8-OH-dG
adducts [32]. Further studies will be required to resolve
this issue, but β -cells in type 2 diabetes may well suffer
from both nuclear and mitochondrial DNA damage, lead-
ing to decreased β -cell function and eventual loss of β -cell
mass.
In this study, both the area and the intensity of Ogg1
staining were assessed. Since it was not practical to collect
specimens in a controlled manner, it could be argued that
differences in fixation technique could affect the fluores-
cence intensity of the immunostaining. However, as we
also detected a significant increase in the islet area stained
for Ogg1, we are confident that islet cell Ogg1 is actually
upregulated in type 2 diabetes. The direct correlation be-
tween the fluorescence intensity and the duration of dia-
betes that held true for samples collected from disparate
locations also argues in favor of the hypothesis. It is inter-
esting that the Ogg1 positive area did not show the same
increase with increasing duration of diabetes as the Ogg1
staining intensity. We have observed that the number of β -
cells varies considerably in the islets from type 2 diabetic
subjects and that large areas of the islets are sometimes re-
placed by amorphous material (data not shown), proba-
bly reflecting fibrosis or amyloidosis. Such a variation in
cell number per islet would bias a correlation of Ogg1
Figure 3
Islet area stained for Ogg1. Islets were semi-quantitatively scored according to Methods into five different groups depend-
ing on the percentage of the area stained positive for Ogg1. The frequency distribution of the scoring in normal and diabetic
subjects shows that it is shifted to the left in islets from type 2 diabetic subjects.BMC Endocrine Disorders 2002, 2 http://www.biomedcentral.com/1472-6823/2/2
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positive cells with duration of diabetes. Moreover, it is
possible that β -cells from patients with longstanding dia-
betes have a higher threshold for an apoptotic response to
DNA-damage than β -cells in normal subjects, as it has
been shown that this threshold increases with age [43].
Consequently, β -cells with high levels of DNA damage
from younger individuals with a shorter duration of dia-
betes might be eliminated by apoptosis, while similarly
damaged β -cells from older individuals, who are likely to
have had diabetes for a longer time may be resistant to ap-
optosis and so remain. Such an apoptotic defect could ac-
count for the increasing intensity of Ogg1 staining,
following accumulated levels of 8-OH-dG adducts with
longer duration of diabetes. Further epidemiological stud-
ies in which age was specifically studied would be re-
quired to address this issue more definitively.
We noted that the variability in the amount of Ogg1 stain-
ing is higher in the control group than in the samples
from the diabetic patients. It is well known that there is a
high incidence of undiagnosed diabetes in the general
population. Since detailed patient records were not avail-
able, it is possible that undiagnosed diabetes in the con-
trol group could account for the increased variability.
Ogg1 knockout mice possess increased levels of 8-OH-dG
in their genome, particularly in the mitochondrial ge-
nome, but do not seem to exhibit an increased frequency
of malignancies [44–46]. It was postulated that the conse-
quences of 8-OH-dG adducts and Ogg1 deficiency affects
mainly cells with high oxygen metabolism and slow pro-
liferation, such as liver cells [45]. While β -cells were not
examined in that study, they certainly exhibit both high
oxidative metabolism and a low rate of proliferation, con-
sistent with them being a target for the effects of 8-OH-dG
adducts. It would be of great interest to study the Ogg1
mutant mice to determine whether an increase level of 8-
OH-dG adducts predisposes to diabetes. This would be
Figure 4
Ogg1 fluorescent staining intensity. Islets were semi-quantitatively scored according to Methods into three different
groups depending on the islet Ogg1 fluorescent intensity. Islets from type 2 diabetic subjects (2, 7, 15, 20, 23 years of diabetes
duration, red) have significantly higher islet Ogg1 fluorescent intensity (P < 0.02) than islets from healthy controls (a-g, green).BMC Endocrine Disorders 2002, 2 http://www.biomedcentral.com/1472-6823/2/2
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important in establishing oxidative DNA damage as a
causal mechanism in diabetes as opposed to merely being
an epiphenomenon in which the important targets for di-
abetes pathogenesis lie elsewhere in the β -cell. Further ep-
idemiological studies of Ogg1 expression as well as
studies of the expression of other genes and proteins that
are involved in DNA damage responses should also be
performed to further test the hypothesis that DNA damage
is involved in the pathogenesis of type 2 diabetes.
Conclusions
We conclude that the expression of the DNA repair en-
zyme Ogg1 is up-regulated in islets from type 2 diabetic
specimens. Moreover, Ogg1 expression intensity is direct-
ly correlated with the duration of diabetes. These finding
are consistent with the hypothesis that oxidative DNA
damage is playing a role in the pathogenesis of β -cell dam-
age in type 2 diabetes.
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Figure 5
Ogg1 fluorescent staining intensity. Islets were semi-quantitatively scored according to Materials and Methods into three
different groups depending on the islet Ogg1 fluorescent intensity. The frequency distribution of the scoring in normal and dia-
betic subjects shows that it is shifted to the left in islets from type 2 diabetic subjects. Fluorescent intensity is expressed as
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